Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks.

On December 12, 2025, Morgan Stanley analyst Terence Flynn reiterated an Equal Weight rating on MRK and raised the price target from $100 to $102 in a research note to investors.

On the same day, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an expanded indication for MRK’s WINREVAIR (sotatercept) for adults with Pulmonary Arterial Hypertension (PAH) covering WHO Functional Classes II–IV. This recommendation will now be reviewed by the European Commission, with a final decision expected in the first quarter of 2026.

Merck & Co., Inc. (MRK) Sees Mixed Analyst Views as Europe Advances WINREVAIR Review

Earlier on December 10, 2025, TheFly reported that HSBC analyst Rajesh Kumar reiterated a Buy rating on Merck & Co., Inc. (NYSE:MRK) and raised the price target to $120

In addition, MRK’s Animal Health segment received conditional approval from the U.S. Food and Drug Administration (FDA) in early December 2025 for EXZOLT CATTLE‑CA1, a pour‑on parasiticide formulation effective against cattle infestations.

Merck & Co., Inc. (NYSE:MRK) is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.